C4 Therapeutics Inc
For the period ended Sep 30, 2024. Filed Oct 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 31, 2024
CCCC$3.00-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows used in operating activities: | ||
| Net loss | $(70,743) | $(97,739) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Stock-based compensation expense | 21,427 | 20,876 |
| Depreciation and amortization expense | 1,338 | 1,450 |
| Reduction in carrying amount of right-of-use asset | 4,790 | 4,596 |
| Net accretion of discounts on marketable securities | (4,315) | (2,817) |
| Amortization of debt discount − related party | — | 405 |
| Loss on early extinguishment of debt | — | 621 |
| Other | 53 | 120 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 1,458 | 973 |
| Prepaid expenses and other current and long-term assets | (4,300) | 1,404 |
| Accounts payable | 57 | 104 |
| Accrued expenses and other current liabilities | (5,242) | (3,866) |
| Operating lease liability | (3,881) | (3,489) |
| Deferred revenue | 12,133 | (5,467) |
| Net cash used in operating activities | (47,225) | (82,829) |
| Cash flows (used in) provided by investing activities: | ||
| Proceeds from maturities of marketable securities | 178,781 | 219,975 |
| Purchases of marketable securities | (243,537) | (92,020) |
| Purchases of property and equipment, net | (184) | (1,551) |
| Net cash (used in) provided by investing activities | (64,940) | 126,404 |
| Cash flows provided by (used in) financing activities: | ||
| Proceeds from issuance of common stock pursuant to the at-the-market equity program, net | 24,370 | — |
| Proceeds from issuance of common stock pursuant to the Betta Pharma Stock Purchase Agreement | 20,000 | — |
| Proceeds from exercise of stock options | 667 | 58 |
| Payments for repurchase of common stock for tax withholding | (194) | (110) |
| Payment of long-term debt − related party | — | (12,500) |
| Other | 381 | 369 |
| Net cash provided by (used in) financing activities | 45,224 | (12,183) |
| Net change in cash, cash equivalents and restricted cash | (66,941) | 31,392 |
| Cash, cash equivalents and restricted cash at beginning of period | 130,033 | 33,033 |
| Cash, cash equivalents and restricted cash at end of period | $63,092 | $64,425 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash, cash equivalents and restricted cash at end of period | $63,092 | $64,425 |
| Less: restricted cash | (3,443) | (3,454) |
| Cash and cash equivalents at end of the period | $59,649 | $60,971 |
Condensed Consolidated Statements of Cash Flows - Continued
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for leases | $6,614 | $6,421 |
| Cash paid for income taxes | $— | $1,003 |
| Cash paid for interest − related party | $— | $990 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.